"Wegovy Receives FDA Approval for Heart Disease Prevention"
TL;DR Summary
The FDA has approved a new use for the weight loss drug Wegovy, allowing it to be used to reduce the risk of heart attacks, strokes, and cardiovascular-related death in adults with heart disease who are overweight or have obesity. The approval was based on a study showing that participants who took Wegovy had a lower risk of these events compared to those who received a placebo. This new indication may lead to broader insurance coverage for the medication, but the high cost of the drug could pose challenges for coverage by employers and health plans.
- Wegovy Approved By FDA to Reduce Heart Attack Risk The New York Times
- Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug Fox Business
- Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage CNBC
- Novo's obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion FiercePharma
- FDA Approves Wegovy For Heart Conditions in Game-Changing Move ScienceAlert
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
2 min
vs 3 min read
Condensed
78%
431 → 96 words
Want the full story? Read the original article
Read on The New York Times